Company Research Report: BIOTRONIK

Company Overview

Name: BIOTRONIK

Mission: "Excellence For Life." BIOTRONIK focuses on developing life-changing cardiovascular and endovascular solutions with trusted and innovative technology to improve patient care.

Founded: 1963

Founder: Prof. Max Schaldach

Key People:

• Dr. Alexander Uhl, CEO

• Ryan Walters, President (BIOTRONIK US)

• David Hayes, M.D., Chief Medical Officer

Headquarters: Berlin, Germany

Global Presence: Represented in over 100 countries with U.S. operations in New York City, New York and Lake Oswego, Oregon.

Number of Employees: No information is available.

Revenue: No information is available.

Known For: BIOTRONIK is known for its pioneering innovations in cardiac rhythm management, vascular intervention, and electrophysiology. They focus on pacemakers, stents, implantable defibrillators, and remote monitoring services.

Products

Cardiac Rhythm Management

• Pacemakers, Implantable Defibrillators, and Leads:

• Comprehensive portfolio designed to help the human heart beat optimally.

• Technologies such as Closed Loop Stimulation, and DX Technology.

• Home Monitoring:

• Provides remote monitoring systems for patients with cardiac arrhythmias.

Vascular Intervention

• Stents and Balloon Catheters:

• The world's first 4 F-compatible stent (Pulsar) for treating long lesions.

• Introduced Orsiro, the first hybrid drug-eluting stent in the industry.

• Guide Wires:

• Comprehensive range designed for coronary and peripheral artery disease.

Electrophysiology

• State-of-the-Art Catheters:

• Used for diagnosing and treating cardiac arrhythmias.

Additional Technologies

• ProMRI:

• Offers technology compatible with MRI environments.

• Zero-Gravity:

• Provides increased safety and comfort for clinicians.

• Renamic Programmer:

• Provides in-situ device programming for implantable devices.

Recent Developments

• FDA Approvals:

• FDA approval for Amvia Edge Pacemakers.

• Pulsar-18 T3 receives FDA approval.

• Prospera™ Spinal Cord Stimulation System approved by FDA.

• FDA approval for the first stylet-driven lead and dedicated delivery catheter for LBBAP.

• Product Launches:

• Announced and received approval for BIOTRONIK’s Orsiro® Mission DES for improved deliverability and outcomes.

• BIOMONITOR IV, focused on intelligence and clarity in patient monitoring.

• Partnerships and Collaborations:

• Collaboration with IMDS for complex medical solutions.

• Market Stance:

• Exclusively supplying DX models for new single-chamber ICD implants, focusing on proprietary DX Technology due to clinical evidence supporting superior diagnostics.

• Research and Publications:

• Published the first expert recommendations on remote management of Spinal Cord Stimulation Systems.

• Clinical Studies:

• The BIO-CONDUCT trial showed high implant success and low complication rates for Solia S leads in LBBAP.

Conclusion

BIOTRONIK stands as a pioneering force in the medical technology industry, dedicated to enhancing the lives of patients globally. The company upholds its core mission of providing "Excellence For Life" through its innovative and trusted cardiovascular and endovascular solutions. Their commitment is reflected in continuous research, strategic partnerships, and robust product portfolios that adhere to the highest quality standards. They work closely with healthcare professionals to positively impact patient care, solidifying their role as a leader in medical device technology.